Izvorni znanstveni članak
INFLUENCE OF BIOLOGICAL THERAPEUTICS ON PATIENT-REPORTED QUALITY-OF-LIFE OUTCOMES (WHOQOL-BREF), FUNCTIONAL SCORES AND DISEASE ACTIVITY AMONG CROATIAN PATIENTS WITH RHEUMATOID ARTHRITIS: OUR EXPERIENCE
Ana Gudelj Gračanin
; Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, School of Medicine University of Zagreb, Dubrava University Hospital, Zagreb, Croatia
Aldenita Matić
; Department of Psychiatry, Dubrava University Hospital, Zagreb, Croatia
Tea Mikula
; School of Medicine University of Zagreb, Zagreb, Croatia
Jasminka Dobša
; Faculty of Organization and Informatics, University of Zagreb, Varaždin, Croatia
Iva Žagar
; Clinic for Rheumatic Diseases and Rehabilitation, University Hospital Centre Zagreb, Zagreb, Croatia
Lana Mužinić Marinić
; Department of Psychiatry, Dubrava University Hospital, Zagreb, Croatia
Jadranka Morović-Vergles
; Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, School of Medicine University of Zagreb, Dubrava University Hospital, Zagreb, Croatia
Sažetak
Background: Rheumatoid arthritis (RA) is a chronic and disabling disease with a great impact on the quality of life (QOL). The
aim of this study was to assess QOL and health in RA patients treated with biological disease-modifying drugs (bDMARDs) as
opposed to those treated with conventional synthetic DMARDs (csDMARDs). We analysed four domains of QOL: physical health (D1), mental health (D2), social relationships (D3) and one's surroundings (D4); as well as general quality of life (W1), general state of health (W2), and disease activity and physical disability.
Subjects and methods: Seventy-seven RA patients (group A=29 on bDMARDs, group B= 48 on csDMARDs) were enrolled in the study. QOL was evaluated using WHO questionnaire (WHOQOL-BREF), disease activity using Disease ActivityScore28C-reactive protein (DAS28CRP) and functional status using Health Assessment Questionnaire (HAQ).
Results: There was no statistically significant difference of mean values in the four domains of QOL, nor in the general QOL, between groups A and B. There was also no statistically significant difference regarding RA activity (3.51 vrs 3.54, p=0.56). However, we have found that the variable of the general state of health domain was statistically significantly higher in group B (2.66 vrs 2.89, p=0.001), while HAQ was statistically significantly higher in group A (1.19 vrs 1.07, p=0.018), as well as the duration of RA (6.25vrs 3.75 years, p=0.0006). Statistically significant correlation was found between HAQ and W2, disease duration and D3 in group A and DAS28CRP and D1, D2, W2 and HAQ and D1 and D2 in group B.
Conclusion: These findings suggest that the inclusion of bDMARDs in the treatment regimen was overdue, with RA already
advancing with developed functional disability, which prevented the achievement of the primary goals of treatment: low disease
activity or remission and the improvement of patient's QOL.
Ključne riječi
rheumatoid arthritis; quality of life; QOL; biological therapy; bDMARDs
Hrčak ID:
262642
URI
Datum izdavanja:
18.11.2020.
Posjeta: 297 *